Recipients of heart transplants are treated with powerful immunosuppressants to prevent organ rejection, but complications still occur. Early signs of rejection are often monitored by an invasive procedure that requires heart tissue biopsy. A noninvasive diagnostic test was recently approved in the United States, in which blood cells from heart transplant recipients are monitored for the expression of genes associated with immune-mediated rejection.
展开▼